Literature DB >> 19058341

A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody.

Jin Xu1, Chuan-Hua Yang, Xiao-Yu Chen, Xu-Hang Li, Min Dai, Shu-Dong Xiao.   

Abstract

A small subset of patients with active ulcerative colitis is non-responsive to major known non-biological therapies. We reported 5 patients with positive serum proteinase-3 antineutrophil cytoplasmic antibody (PR3-ANCA) and tried to (1) identify the common clinical features of these patients; (2) investigate the efficacy of a novel therapy using a Chinese medicine compound; and (3) attract more gastroenterologists to be engaged in further study of this subset of patients. The common manifestations of disease in these 5 patients included recurrent bloody diarrhea and inflammatory lesions involving the entire colorectal mucosa. Initial treatment with intravenous methylprednisolone successfully induced remission. Four of these 5 patients were steroid-dependence, and immunosuppressants, such as azathioprine and cyclophosphamide, were ineffective. In 3 patients, only the particular Chinese medicine compound could induce and maintain remission. One patient underwent colectomy. No vascular inflammatory lesions were found by histopathological examination. Although more cases are needed for confirmation, our study indicates that ulcerative colitis with positive PR3-ANCA may belong to a subtype of refractory ulcerative colitis. The particular Chinese medicine compound used in our study is by far the most effective in the management of these patients, with additional advantages of having no noticeable side-effects and less financial burden.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058341      PMCID: PMC2773869          DOI: 10.3748/wjg.14.7012

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  J F Quinton; B Sendid; D Reumaux; P Duthilleul; A Cortot; B Grandbastien; G Charrier; S R Targan; J F Colombel; D Poulain
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

2.  The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis.

Authors:  A N Elzouki; S Eriksson; R Löfberg; L Nässberger; J Wieslander; S Lindgren
Journal:  Inflamm Bowel Dis       Date:  1999-11       Impact factor: 5.325

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  [The diagnostic significance of antineutrophil cytoplasmic antibodies in ulcerative colitis].

Authors:  X Liu; T Yu; M Zhao; X Tang; Q Gu; N Liu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1999-07

5.  A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.

Authors:  J A Rump; J Schölmerich; V Gross; M Roth; R Helfesrieder; A Rautmann; J Lüdemann; W L Gross; H H Peter
Journal:  Immunobiology       Date:  1990-11       Impact factor: 3.144

6.  Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  G Cambridge; D S Rampton; T R Stevens; D A McCarthy; M Kamm; B Leaker
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

7.  Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.

Authors:  A Stallmach; B M Wittig; C Moser; J Fischinger; R Duchmann; M Zeitz
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 8.  Cyclosporine A for induction of remission in severe ulcerative colitis.

Authors:  O Shibolet; E Regushevskaya; M Brezis; K Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

9.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

Review 10.  ANCA-associated vasculitis: diagnostic and therapeutic strategy.

Authors:  Shoichi Ozaki
Journal:  Allergol Int       Date:  2007-05-01       Impact factor: 5.836

View more
  4 in total

1.  Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.

Authors:  Maria Teresa Arias-Loste; Geovana Bonilla; Irene Moraleja; Michael Mahler; Miguel Angel Mieses; Beatriz Castro; Montserrat Rivero; Javier Crespo; Marcos López-Hoyos
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

2.  Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Authors:  Gregorios Christodoulidis; Konstantinos Perivoliotis; Anastasios Manolakis; Alexandros Diamantis; Apostolos Koffas; Dimitrios Magouliotis; Vasiliki Pappi; Dimitrios Zacharoulis
Journal:  Case Rep Gastrointest Med       Date:  2020-03-23

3.  Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  Juliana Goldbaum Crescente; Alessandra Dellavance; Marcio Augusto Diniz; Flair Jose Carrilho; Luis Eduardo Coelho de Andrade; Eduardo Luiz Rachid Cançado
Journal:  Clinics (Sao Paulo)       Date:  2021-02-05       Impact factor: 2.365

Review 4.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.